Anteris Advances PARADIGM Trial with $320M Capital Raise and U.S. Enrollment
Event summary
- Anteris raised $320M in January 2026 to support the PARADIGM Trial and global commercialization of the DurAVR® THV System.
- U.S. enrollment in the PARADIGM Trial commenced post-Q1 2026, following European recruitment.
- CMS coverage determination is expected to facilitate U.S. patient recruitment and site adoption.
- Q1 2026 operating cash outflows were $28.7M, driven by clinical, regulatory, and manufacturing expenses.
The big picture
Anteris' progress in the PARADIGM Trial and U.S. enrollment marks a critical phase in the structural heart device market, where competitive differentiation hinges on clinical trial outcomes and regulatory support. The company's ability to scale manufacturing and maintain operational momentum will be key to its global commercialization strategy.
What we're watching
- Trial Execution
- The pace at which Anteris activates additional countries and sites in the PARADIGM Trial will determine the timeline for commercial launch.
- Regulatory Momentum
- Whether CMS coverage will sustain U.S. site activation and patient enrollment momentum.
- Financial Sustainability
- How Anteris balances high operating cash outflows with its $320M capital raise to support long-term trial and commercialization efforts.
Related topics